New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
12:22 EDTIGT, RSH, VRX, IDIX, SGMS, AGN, FRAN, MRK, ACHNOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday, threatening to break their recent winning streak. The market has steadily moved higher over the past week and has seen the Dow and S&P move to all-time highs, albeit on very light volume. ECONOMIC EVENTS: In the U.S., wholesale inventories rose 1.1% in April, with sales up 1.3%, which were both better than forecast. The JOLTS report showed job openings climbed 289K to 4.46M in April. In China, official data showed an index of consumer prices rose 2.5% year-on-year in May, while China's producer price index contracted 1.4% during the month. COMPANY NEWS: Allergan (AGN) once again rejected the takeover proposal being made by Valeant (VRX) in partnership with hedge fund Pershing Square, saying that their upwardly revised bid still "substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the company and its stockholders." Allergan said in a letter to Valeant that it publicly disclosed that the Allergan board has "serious concerns" about the large stock component of the proposal and that the latest Valeant proposal does not warrant discussions between the companies. Following the latest twist in this ongoing story, shares of Allergan were fractionally lower, while Valeant was down a bit over 1%. MAJOR MOVERS: Among the notable gainers was Achillion (ACHN), which rose another 54% near noon after having gained 47% yesterday. This morning JMP Securities upgraded Achillion following Merck's (MRK) acquisition of Idenix (IDIX) yesterday, while Piper Jaffray became the latest Street research firm to say it believes Achillion is positioned as an acquisition target. Also, Achillion announced that the FDA has removed the clinical hold on sovaprevir, an NS3/4A protease inhibitor, to permit the conduct of trials in patients with HCV. Also higher for a second straight session was Scientific Games (SGMS), which rose nearly 13% after the company announced the appointment of a new President and CEO. The company's shares had risen yesterday after Reuters said another company in the same space, International Game Technology (IGT), was exploring a sale and has attracted interest from rival gaming companies and private equity firms. Among the noteworthy losers was apparel, jewelry, and accessories retailer Francesca’s (FRAN), which sunk more than 13% after the company's first quarter quarter results fell short of analysts' consensus estimates and it cut its fiscal 2014 outlook. Also lower following its own earnings report was RadioShack (RSH), which declined over 9% after reporting a Q1 loss that exceeded analyst's expectations and warning that it may need to borrow additional funds or raise capital if the current trend in its operating results continues or further declines. INDEXES: Near midday, the Dow was down 14.18, or 0.08%, to 16,928.92, the Nasdaq was down 6.62, or 0.15%, to 4,329.62, and the S&P 500 was down 3.39, or 0.17%, to 1,947.88.
News For AGN;VRX;ACHN;SGMS;RSH;MRK;IDIX;IGT;FRAN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 24, 2015
12:22 EDTACHNAchillion spokesperson says EASL presentation not canceled, Bloomberg reports
Subscribe for More Information
11:22 EDTACHNAchillion strength attributed to rumor of canceling presentation
Subscribe for More Information
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.
07:58 EDTMRKMerck May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
05:35 EDTMRKMerck Phase 3 C-EDGE program shows high sustained virologic responses
Subscribe for More Information
April 23, 2015
16:39 EDTMRKACETO subsidiary to launch Timolol Maleate Ophthalmic Solution
Subscribe for More Information
05:40 EDTMRKMerck announces results from C-SURFER Phase 2/3 study
Subscribe for More Information
April 22, 2015
08:18 EDTMRKOrganovo enters into a collaboration agreement with Merck Sharp and Dohme
Subscribe for More Information
April 21, 2015
08:30 EDTMRKMerck reaffirms commitment to developing medicines for infectious diseases
Merck reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. At this year’s 25th European Congress of Clinical Microbiology and Infectious Diseases, April 25-28 in Copenhagen, Denmark, researchers are scheduled to present more than 30 scientific data presentations on the company’s broad portfolio of marketed and investigational anti-infective medicines. Merck completed its acquisition of Cubist Pharmaceuticals, Inc. on Jan. 21, 2015, and continues to build on both companies’ work in infectious disease. Antimicrobial research remains an important area of focus. In addition to a combined portfolio of antibiotic and antifungal medicines, vaccines, and medicines for HIV and HCV, Merck has multiple programs that span discovery through late-stage development. In total, Merck currently has more than 15 ongoing clinical trials evaluating antibiotic, antifungal and antiviral agents for the prevention and treatment of infectious disease. These trials are projected to enroll approximately 8,000 patients.
April 20, 2015
08:05 EDTMRKTetraLogic, Merck enter into oncology clinical study collaboration
Subscribe for More Information
07:20 EDTMRKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 19, 2015
19:35 EDTMRKMerck to swiftly repay $5B loan, explore acquisitions by late 2017, Reuters says
Subscribe for More Information
15:21 EDTMRKMerck announces new data from Keytruda study
Subscribe for More Information
14:59 EDTMRKMerck's Keytruda 'superior' to ipilimumab for PFS in patients with melanoma
Subscribe for More Information
14:47 EDTMRKMerck submits supplemental biologics license for Keytruda in lung cancer
Subscribe for More Information
14:31 EDTMRKMerck reports 28% Keytruda response rate in 25 pleural mesothelioma patients
Subscribe for More Information
April 15, 2015
17:07 EDTIGTInternational Game subsidiary awarded $75M-$80M Minnesota Lottery contract
International Game subsidiary GTECH Corporation has entered into a contract with the Minnesota State Lottery to provide new lottery technology, an IP-communications network, multimedia displays, self-service products, and ongoing support services, following a competitive procurement. The 7.5 year integrated services contract with the Lottery contains three renewal options of one year each, or up to one renewal of three years, or any variation thereof. The company expects to receive approximately $75M-$80M in revenues over the base 7.5 year contract period, which runs through August 9, 2023.
10:36 EDTSGMSBofA/Merrill U.S. credit analysts hold an analyst/industry conference call
Subscribe for More Information
08:33 EDTMRKFDA panel results positive for Merck, says SunTrust
Subscribe for More Information
April 14, 2015
13:32 EDTMRKMerck, NewLink Genetics confirm initiation of Phase 3 trial of Ebola vaccine
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use